Thursday, May 1, 2014
The latest Health Policy Brief from Health Affairs and the Robert Wood Johnson Foundation examines the Compounding Quality Act, a law signed by President Obama in November 2013, which seeks to fill the gaps in the Food and Drug Administration’s (FDA’s) inspection and enforcement oversight of compounding pharmacies.
This law was enacted in the wake of a 2012 fungal meningitis outbreak, linked to a Massachusetts drug compounding company. The outbreak caused more than 700 people to become ill and left sixty-four dead. Before the new law was passed, compounding pharmacies were primarily regulated by states, not the FDA.
more information found here
This law was enacted in the wake of a 2012 fungal meningitis outbreak, linked to a Massachusetts drug compounding company. The outbreak caused more than 700 people to become ill and left sixty-four dead. Before the new law was passed, compounding pharmacies were primarily regulated by states, not the FDA.
more information found here
Hospira makes progress on plant problems, reports improved financials
In the past, Hospira ($HSP) competitors have been able to take advantage of the drugmaker's absence from a market because of its plant problems, filling the void and their pockets as well, at Hospira's expense. More recently it has been Hospira's chance to live large off of the quality issues of others. The company's improved Q1 earnings were, in part, due to "off contract" prices.
continue to read here
continue to read here
Florida Board of Pharmacy Board Conference Call Meeting Today, May 1, 2014 to discuss rule 1. Rule 64B16-27.700
May 1, 2014 Board Conference Call
Meeting Location:Telephone Conference Call
Meet Me #:
(888) 670-3525
Participation Code:
513-489-6685
4042 Bald Cypress Way
Tallahassee, FL 32399
Meeting Materials
FAR Notice (PDF) | Agenda (PDF)
Meeting Location:Telephone Conference Call
Meet Me #:
(888) 670-3525
Participation Code:
513-489-6685
4042 Bald Cypress Way
Tallahassee, FL 32399
Meeting Materials
Subscribe to:
Posts (Atom)